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Purpose: Inﬂammation and vascular disease have recently been shown
to play a role in the pathogenesis of osteoarthritis (OA). Low dose
aspirin is commonly used in the prevention of cardiovascular disease.
Its effects have been attributed to a variety of actions, including anti-
inﬂammatory effects and effects on platelet function (both anti-
thrombotic and anti-inﬂammatory) and lipids. However whether it
affects human joints has not been studied. The aim of this study was to
examine whether the use of low dose aspirin affects change in knee
cartilage volume over 2 years.
Methods: 117 people with symptomatic knee OA underwent magnetic
resonance imaging of the knee at baseline and 2 years later. Medial and
lateral tibial cartilage volumes weremeasured using validatedmethods.
Annual absolute change and annual percentage change in cartilage
volumewere calculated. Information about regular low dose aspirin use
was collected at baseline, 6, 12 and 24 months. Participants who re-
ported taking regular low dose aspirin (<¼ 150 mg per day) at more
than 1 time point were deﬁned as being aspirin users.
Results: Twenty six participants reported taking aspirin at more than
one visit, with 91 not taking aspirin. At baseline, the only signiﬁcant
difference between the 2 groups was that those taking aspirin were
older than those who did not (p ¼ 0.03).
In those taking aspirin, annual change in medial tibial cartilage volume
and annual percentage change in cartilage volume was approximately
half that seen in those not taking aspirin (-50 vs. -102mm3 and -2.5% vs.
-5.5%, respectively, P¼0.04 for both). These differences became more
signiﬁcant after adjusting for age, gender, body mass index, initial
cartilage volume and severity of radiographic change in the medial
compartment. The annual change in medial tibial cartilage volume was
-40 mm3 (95% conﬁdence interval (CI) -83, 1.3) in aspirin users vs. -105
mm3 (95% CI -127, -82) in non-aspirin users (P ¼ 0.009 for difference).
The annual percentage change in medial tibial cartilage volume was
-2.0% (95% CI -4.6, 0.53) in aspirin users vs. -5.6% (95% CI -6.9, -4.0) in
non-aspirin users (P¼0.02 for difference). There were no signiﬁcant
differences observed in change in lateral tibial cartilage volume.
Conclusion: This study showed that in people with knee OA, the use of
low dose aspirinwas associatedwith reducedmedial tibial cartilage loss
over 2 years. This requires conﬁrmation in a randomised controlled
trial. If this hypothesis were proven, aspirin may provide a cost effective
disease modifying therapy for OA as it is a cheap medication that is
already in common use and known to be well tolerated.462
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Purpose: The surface bound tyrosine kinase receptor Ddr2 has been
reported to play a role in early osteoarthritis (OA) pathogenesis.
Increased levels of HtrA1 and degradation of the chondrocyte peri-
cellular matrix expose collagen II ﬁbrils, which activate Ddr2 upon
binding, and lead to increased expression and activation of MMP-13.
Pathology is delayed in surgically induced OA in Ddr2+/-mice, and Ddr2,
HtrA1 and MMP-13 are all increased in a spontaneous model of OA in
Col11a1+/- mice from 6 months of age. S100A8 and S100A9 have also
been implicated in the induction of chondrocyte MMP-13, and are well
known to be up-regulated at both the mRNA and protein level in
inﬂammatory mouse models of arthritis. In contrast to inﬂammatory
models, in a surgically-induced post-traumatic OA, chondrocyte S100A8
and S100A9 mRNA are up-regulated but they are not detected in
cartilage at the protein level. The aim of this study was to determine if
there is a link between the Ddr2 pathway and S100A8 and/or S100A9 in
the pathogenesis of OA cartilage pathology by examining S100A8 and
A9 expression in the Coll11a1+/- model where Ddr2 and HtrA1 are
present, and by determining the effect of S100A8 and S100A9 on Ddr2
and HtrA1 expression in mouse cartilage.Methods: S100A8 and S100A9 expression was examined in the knee
cartilage of Col11a1+/- mice and wild-type (WT) littermates at 3 and 9
months of age using immunohistochemistry (n¼ 3 of both genotypes at
both times; archival sections from mice with antigen-induced arthritis
(AIA) used as a positive control).
Mouse femoral head cartilage explants were dissected from 15WTmice
between the ages of 6-8 weeks old, homogenised, and the explanted
cartilage distributed evenly amongst wells, and cultured in serum-free
media  0.1mM murine S100A8 or S100A9 for 24 hours (n¼2 wells/
treatment). Gene expression of Ddr2, HtrA1 was determined by quan-
titative RT-PCR and normalised to Gapdh expression.
Results: S100A9 protein was not detected in the cartilage of 3 or 9
month old mice of either genotype although strong positive staining
was observed in bone marrow of all mice, as well as cartilage from AIA
animals. In addition to marrow and AIA cartilage samples, S100A8
protein was weakly detected in some chondrocytes/pericellular matrix
in non-calciﬁed cartilage in 1 of the 3 WT and Coll11a1+/- mice at 3
months of age. In contrast S100A8 was localized to chondrocytes/per-
icellular matrix of non-calciﬁed cartilage and meniscal cells in all 9
month old animals, with no difference observed between genotypes. In
mouse femoral cartilage explant cultures, gene expression of Ddr2 was
increased by S100A8, but decreased by S100A9, while HtrA1 was
decreased by both S100A8 and S100A9.
Conclusions: Whilst S100A8 staining was observed in non-calciﬁed
cartilage of some 3 month old and all 9 month old mice, there was no
differential regulation between genotypes, suggesting that whilst an
increase in S100A8 in cartilage may be an age-related change, it is not
associated with the accelerated cartilage degradation seen in the
Col11a1+/- model. In contrast, no S100A9 staining was observed in the
cartilage of any mice from either genotype or age, and therefore may
not be associated either with OA- or age-related cartilage changes. Gene
expression data from femoral head cartilage cultures, however, suggests
that S100A8 but not S100A9 can increase Ddr2 mRNA, providing a link
between these degradative cartilage pathways. However the down-
regulation of HtrA1 mRNA by the S100 proteins suggests that an alter-
native mechanism for exposure of the Ddr2 ligand would be required.
Taken together, this data suggests that whilst S100A8 is not associated
with cartilage degradation in Col11a1+/-, it may pre-dispose the cartilage
to degradation via up-regulation of Ddr2.
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Introduction: Osteoarthritis (OA) is a degenerative disorder associated
with the breakdown of articular cartilage. The mechanisms responsible
for this condition are not well understood and therefore no treatments
exist to halt or delay the progression of OA. Recent ﬁndings from our
laboratory indicate that activation of the transcription factor PPARdelta
induces the expression of enzymes involved in proteoglycan breakdown
and can lead to cartilage degeneration in OA, prompting us to speculate
whether inhibition of PPARdelta, can protect from cartilage breakdown
in OA.
Purpose: To evaluate the role of PPARdelta in Osteoarthritis through all
encompassing in-vitro, ex-vivo and in-vivo models of disease.
Methods: To test this, human chondrocytes and mouse femoral head
cartilage explants were treated with pharmacological agonist
(GW501516) and antagonists of PPARdelta (GSK3787/0660) to evaluate
changes in gene expression (qPCR), and histology (Safranin-O, immu-
nohistochemistry) consistent with OA, and to determine if recoverywas
possible.
Our in-vivo approach uses the Cre-Lox system to inactivate PPARdelta
speciﬁcally in the cartilage of using a surgical model of OA. Mutant and
control mice aged 20 weeks are being compared 8 weeks after
a destabilization of medial meniscus (DMM) surgery, based on the
principle that changes in biomechanical load drive cartilage degener-
ation. In order to assess the progression of OA between groups, histo-
pathological scoring (OARSI) and immunohistochemistry for known
markers of OA, (MMP 13, cartilage matrix breakdown products) are
being analyzed. Serum analyses for extracellular matrix markers of
cartilage breakdown are being conducted. To investigate changes in
joint loading during OA, mutant and control mice are being compared
through gait analyses using the CatWalk system that measures load on
